Myasthenia Gravis (MG) is a rare, chronic neuromuscular disorder where communication between the nerve and the muscle is disrupted, causing debilitating and potentially life-threatening muscle weakness.1
Myasthenia Gravis (MG) is a rare, chronic neuromuscular disorder where communication between the nerve and the muscle is disrupted, causing debilitating and potentially life-threatening muscle weakness.1
77.7
per million
Approximately 77.7 people out of every million are affected globally2
5.3
new cases per million
On average, 5.3 new cases of MG occur each year for every million people2
MG symptoms can differ significantly from person to person, which means the path to a diagnosis is not the same for everyone.3 Although MG can develop at any age, women with MG are typically diagnosed at <40 years old compared to men aged >50 years old.4 Patients often face significant delays in diagnosis due to the unpredictable nature of the disease, which makes it difficult to detect during clinical exams.5-8
Some MG symptoms include:4,9
Eyelid drooping
Blurred or double vision
Difficulty speaking
Difficulty chewing/swallowing
Choking
Difficulty supporting neck
Shortness of breath/difficulty breathing
Weakness in arms and legs
Fatigue from repeated muscle use
MG has several autoantibody subtypes, defined by the target protein:
The types of MG described above are some commonly recognized forms of the condition but do not represent all MG subtypes.
People living with MG experience debilitating muscle weakness, which can lead to difficulties with vision, mobility, speaking, swallowing, and even breathing. As a result, they may lose the ability to perform daily activities, which can lead to loss of work and personal independence.
For many people, MG affects the ability to manage and complete everyday activities, such as:10, 12-13
Holding arms outstretched
Ability to drive
Climbing stairs and getting out of chairs
Brushing teeth or combing hair
Doing housework
Breathing (in severe cases)
MG occurs when the immune system produces IgG antibodies that block, alter, or damage the neuromuscular junction — the part of the body where the brain tells the muscle to move.14-15 The condition can affect any voluntary muscle, including those controlling eye movements, facial expression, speaking and swallowing, and arms and legs. In more life-threatening cases, MG can affect muscles responsible for breathing.
MG is a debilitating disease, requiring early, assertive treatment for better long-term outcomes. Although many people living with MG respond well to treatment, 15-20% of patients are considered difficult to treat and will continue to experience moderate or severe muscle weakness.16 Commonly used therapies are associated with limitations, such as symptomatic effect only, slow onset of action, and broad/unselective immunosuppression, which may increase treatment burden and can be insufficient in achieving treatment goals.
While there is no cure for MG, advancements in MG treatment research aim to not only treat symptoms, but also to target the underlying causes of the disease. Ask your doctor about which treatment options may be appropriate for you.
Reaching minimal symptom expression (MSE) is an important goal for MG treatment. MSE reflects the point at which MG symptoms are well controlled and have minimal impact on daily life. When treatment strategies are working well, they don’t just control the disease — they help patients feel and live better.
Explore our ongoing clinical trials for MG.
Program:
Efgartigimod
Phase 3 trial of IV efgartigimod for the treatment of AChR-negative Generalized Myasthenia Gravis (gMG).
Program:
Efgartigimod
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Ocular Myasthenia Gravis.
Program:
Efgartigimod
Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis.
Program:
Efgartigimod
Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis.
Program:
Efgartigimod
A Non-interventional, Post-authorisation Safety Study of Patients Treated with Efgartigimod Alfa.
For more information on this disease, please find here additional resources and links to advocacy organizations.
Myasthenia Gravis Foundation of America
myasthenia.org
Conquer MG
www.myastheniagravis.org
Muscular Dystrophy Association
www.mda.org
Myasthenia Gravis Association (Missouri, Kansas, Northwest Arkansas)
www.mgakc.org
Myasthenia Gravis Foundation California
www.myasthenia-ca.org
Myasthenia Gravis Association Colorado
www.4-mga.org
Myasthenia Gravis Foundation of Michigan
mg-mi.org
Myasthenia Gravis Minnesota
www.mgminnesota.com
MG Japan
www.mgjapan.org
Myasthenia Gravis Holistic Society
www.mgholisticsociety.org
Myasthenia Gravis Foundation of America
myasthenia.org
Conquer MG
www.myastheniagravis.org
Muscular Dystrophy Association
www.mda.org
Myasthenia Gravis Association (Missouri, Kansas, Northwest Arkansas)
www.mgakc.org
Myasthenia Gravis Foundation California
www.myasthenia-ca.org
Myasthenia Gravis Association Colorado
www.4-mga.org
Myasthenia Gravis Foundation of Michigan
mg-mi.org
Myasthenia Gravis Minnesota
www.mgminnesota.com
MG Japan
www.mgjapan.org
Myasthenia Gravis Holistic Society
www.mgholisticsociety.org